Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

In recent years PBPC have replaced bone marrow as the source of hematopoietic stem cells for autologous transplantation. One of the cited advantages of this procedure is the avoidance of bone marrow harvest, which frequently requires general anesthesia. Other advantages include faster neutrophil and platelet engraftment times, faster immune recovery, decrease in the amount of tumor contamination and technical ability to obtain stem cells from patients previously considered unharvestable because of marrow fibrosis or because of prior radiotherapy to the pelvis. Filgrastim has emerged as the preferred cytokine for stem cell mobilization based on its safety profile and the positive experience in granulocyte donors however, the number of circulating CD34+ cells does not occur until the third day after starting filgrastim injections. Pegfilgrastim stimulates the production and maturation of neutrophil precursors and enhances the functions of mature neutrophils in the same manner as filgrastim. Data form normal volunteers and in studies of patients with cancer have shown prolonged serum levels of the cytokine, with "self-regulation" of pegfilgrastim levels as a function of the neutrophil count. This confers a therapeutic advantage in clinical settings by allowing a less frequent dosing.

Key facts

Study ID

NCT00067639

Run by

M.D. Anderson Cancer Center

People needed

50

Starts

2003-12-01

Expected to finish

2007-04-01

Last updated by the study team

2012-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1. Age 18 years or older
• Patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation and PBPC cell collection without chemopriming.
• Zubrod performance status < 3 (Appendix E)
• Serum bilirubin < 1.5 times the upper limit of normal, serum SGOT and SGPT < 2 times the upper limit of normal, serum creatinine < 2.0 mg/dl
• WBC > 3,500/ul
• Platelet count > 100,000/ul prior to first apheresis procedure
• Patients should not have received prior chemotherapy. Only patients who have been treated with thalidomide, bortezomib, +/- dexamethasone will be eligible.
• Sufficient peripheral venous access or central venous catheter
• Informed consent

You may not qualify if…

• Serious intercurrent medical illness
• History of bleeding disorders (except patients with treated, myeloma related bleeding disorders)
• Untreated hypercoagulation abnormalities
• Patients with prior history of pulmonary embolism, deep venous thrombosis requiring anticoagulant therapy, or placement of a venous filter.
• Untreated symptomatic cardiac disease defined as left ventricular EF of <40% and NYHA functional class of > II (Appendix F)
• Uncontrolled infection defined as fever or antibiotics within 72 hours of registration.
• History of allergy to filgrastim, pegfilgrastim or known hypersensitivity to E-coli derived proteins.
• Palpable splenomegaly or craniocaudal spleen length greater than 12 cms
• Pregnancy
• Use of aspirin, ibuprofen containing products within 7 days of enrollment
• History of uncontrolled autoimmune disorder
• Sickle cell trait/sickle cell disease
• Women who are lactating or breast feeding
• 14. Patients with abnormal cytogenetics that may be secondary to myelodysplasia (-5, -7 and 11q23 abnormalities) will be excluded
• Peripheral vascular disease

Where it is running

• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.